Nanobiotix S.A. (NBTX)
NBTX Stock Price Chart
Explore Nanobiotix S.A. interactive price chart. Choose custom timeframes to analyze NBTX price movements and trends.
NBTX Company Profile
Discover essential business fundamentals and corporate details for Nanobiotix S.A. (NBTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Dec 2020
Employees
108.00
Website
https://www.nanobiotix.comCEO
Laurent Levy
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
NBTX Financial Timeline
Browse a chronological timeline of Nanobiotix S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 May 2026
Upcoming earnings on 17 Sept 2025
Earnings released on 2 Apr 2025
EPS came in at -$1.01 falling short of the estimated -$0.62 by -63.46%, while revenue for the quarter reached -$21.64M , missing expectations by -709.22%.
Earnings released on 12 Nov 2024
EPS came in at -$0.50 surpassing the estimated -$0.51 by +2.47%, while revenue for the quarter reached $9.99M , missing expectations by -3.45%.
Earnings released on 24 Apr 2024
EPS came in at -$0.33 surpassing the estimated -$0.83 by +60.40%, while revenue for the quarter reached $36.20M .
Earnings released on 13 Nov 2023
EPS came in at -$0.87 falling short of the estimated -$0.59 by -47.60%, while revenue for the quarter reached $3.59M , missing expectations by -9.09%.
Earnings released on 28 Mar 2023
EPS came in at -$0.95 , while revenue for the quarter reached $1.86M .
Earnings released on 9 Nov 2022
EPS came in at -$0.79 , while revenue for the quarter reached $695.08K .
Earnings released on 30 Mar 2022
EPS came in at -$0.54 surpassing the estimated -$1.05 by +48.56%, while revenue for the quarter reached $752.78K , missing expectations by -47.33%.
Earnings released on 9 Aug 2021
EPS came in at -$1.04 falling short of the estimated -$0.60 by -73.76%, while revenue for the quarter reached $11.86K , beating expectations by +3.76%.
Earnings released on 5 May 2021
EPS came in at -$0.57 surpassing the estimated -$1.01 by +43.06%, while revenue for the quarter reached $15.94K , beating expectations by +981.79%.
Earnings released on 23 Oct 2020
EPS came in at -$1.02 surpassing the estimated -$1.09 by +5.92%, while revenue for the quarter reached $41.63K , missing expectations by -98.11%.
NBTX Stock Performance
Access detailed NBTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.